Sanjeev Saksena

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/613835/publications.pdf

Version: 2024-02-01

		218677	82547
77	6,809	26	72
papers	citations	h-index	g-index
0.6	0.6	0.6	2.400
86	86	86	3498
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	AlMâ€AF: A Physician Survey in the United States and Europe. Journal of the American Heart Association, 2022, 11, e023838.	3.7	10
2	Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 2022, 65, 287-326.	1.3	20
3	Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial. American Heart Journal, 2020, 220, 1-11.	2.7	12
4	Clinical classification and the subclinical atrial fibrillation challenge: a position paper of the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 2020, 59, 495-507.	1.3	6
5	Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 325-331.	1.3	7
6	Atrial fibrillation and its pernicious role in heart failure with preserved ejection fraction: a new frontier in interventional electrophysiology. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 89-90.	1.3	2
7	Festina Lenteâ€"a curiously apt aphorism for Interventional Cardiac Electrophysiology in 2018. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 1-3.	1.3	O
8	The Journal turns over a new page in 2019. Journal of Interventional Cardiac Electrophysiology, 2018, 53, 281-281.	1.3	0
9	Agustin ("Tinoâ€) Castellanos Jr. (1927–2017): The Journal Editors honor the grand legacy of a gentleman and a scholar. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 247-249.	1.3	O
10	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 689-697.	4.1	68
11	Atrial resynchronization therapy in patients with atrial fibrillation and heart failure with and without systolic left ventricular dysfunction: a pilot study. Journal of Interventional Cardiac Electrophysiology, 2018, 53, 9-17.	1.3	2
12	Three-dimensional mapping and intracardiac echocardiography in the treatment of sinoatrial nodal tachycardias. Journal of Interventional Cardiac Electrophysiology, 2016, 46, 55-61.	1.3	1
13	Tailoring interventional arrhythmia therapy to individual patients: seeking the Art and the Science of Cardiac Electrophysiology in 2016. Journal of Interventional Cardiac Electrophysiology, 2016, 45, 1-2.	1.3	O
14	Patient care and physician conflicts of interests: the Hydra grows new heads but is any Hercules in sight?. Journal of Interventional Cardiac Electrophysiology, 2015, 42, 1-4.	1.3	1
15	Left atrial reverse remodeling and prevention of progression of atrial fibrillation with atrial resynchronization device therapy utilizing dual-site right atrial pacing in patients with atrial fibrillation refractory to antiarrhythmic drugs or catheter ablation. Journal of Interventional Cardiac Electrophysiology, 2014, 40, 245-254.	1.3	4
16	Building Atrial Fibrillation Awareness: Is it Time to get Beyond the Top Line?. Journal of Atrial Fibrillation, 2013, 6, 908.	0.5	0
17	Clinical trials of antiarrhythmic therapies and optimizing health care resource deployment: the need for a paradigm shift. Journal of Interventional Cardiac Electrophysiology, 2012, 33, 1-3.	1.3	2

Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50

#	Article	IF	Citations
19	Twenty-five years of implantable defibrillator practice in the USA: Are we ready for globalization?. Journal of Interventional Cardiac Electrophysiology, 2011, 30, 1-3.	1.3	1
20	Progression of new onset to established persistent atrial fibrillation: an implantable device-based analysis with implications for clinical classification of persistent atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2011, 32, 7-15.	1.3	13
21	A truly new view from the summit: from translational science to outcomes research in clinical arrhythmology. Journal of Interventional Cardiac Electrophysiology, 2010, 27, 1-2.	1.3	1
22	Intracardiac Echocardiographyâ€Guided Cardiac Resynchronization Therapy: Technique and Clinical Application. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1030-1039.	1,2	18
23	Biatrial, 3-Dimensional Mapping of Human Atrial Fibrillation: Methodology and Clinical Observations. Journal of Atrial Fibrillation, 2009, $1,179.$	0.5	O
24	The future of implantable defibrillator and cardiac resynchronization therapy trials. Journal of Interventional Cardiac Electrophysiology, 2008, 23, 29-39.	1.3	2
25	Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias. American Heart Journal, 2007, 154, 884-892.	2.7	63
26	Achieving global access to heart rhythm therapies in the next decade: A tangible goal. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 163-168.	1.3	4
27	Impact of "hybrid therapy―on long-term rhythm control and arrhythmia related hospitalizations in patients with drug-refractory persistent and permanent atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2007, 18, 127-136.	1.3	6
28	Biatrial and Three-Dimensional Mapping of Spontaneous Atrial Arrhythmias in Patients with Refractory Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2005, 16, 494-504.	1.7	62
29	Implantable Defibrillators Configured for Hybrid Therapy of Persistent and Permanent Atrial Fibrillation: Initial Clinical Experience with a Novel Lead Systemâ^—. Journal of Interventional Cardiac Electrophysiology, 2005, 13, 79-86.	1.3	1
30	Dual Site Right Atrial Pacing can Improve the Impact of Standard Dual Chamber Pacing on Atrial and Ventricular Mechanical Function in Patients with Symptomatic Atrial Fibrillation: Further Observations from the Dual Site Atrial Pacing for Prevention of Atrial Fibrillation Trial. Journal of Interventional Cardiac Electrophysiology, 2005, 12, 177-187.	1.3	24
31	Implantable Rhythm Management Device Failures and Patient/Physician Notification: A Simmering Cauldron Boils Over. Journal of Interventional Cardiac Electrophysiology, 2005, 14, 135-137.	1.3	1
32	Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm, 2005, 2, 125-131.	0.7	184
33	Long-term rhythm control of drug-refractory atrial fibrillation with "hybrid therapy―incorporating dual-site right atrial pacing, antiarrhythmic drugs, and right atrial ablation. American Journal of Cardiology, 2004, 93, 569-575.	1.6	38
34	Peering Through the Looking Glass:. Electrical Therapy for Atrial Fibrillation in 2004-Where Do We Stand?. Journal of Cardiovascular Electrophysiology, 2004, 15, 496-500.	1.7	5
35	Hybrid therapy of atrial fibrillation: algorithms and outcome. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 235-247.	1.3	29
36	Classifications and practice guidelines in atrial fibrillation: a changing landscape. Journal of Interventional Cardiac Electrophysiology, 2003, 8, 5-8.	1.3	2

#	Article	IF	CITATIONS
37	Effectiveness of rhythm control in persistent or permanent atrial fibrillation with overdrive atrial pacing and antiarrhythmic drugs after linear right atrial catheter ablation. American Journal of Cardiology, 2003, 92, 1037-1044.	1.6	7
38	International Consensus on Nomenclature and Classification of Atrial Fibrillation: A Collaborative Project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Journal of Cardiovascular Electrophysiology, 2003, 14, 443-445.	1.7	81
39	Implantable cardioverter-defibrillators in cardiovascular care: technologic advances and new indications. Current Opinion in Critical Care, 2003, 9, 362-368.	3.2	4
40	Management of the Patient With an Implantable Cardioverter-Defibrillator in the Third Millennium. Circulation, 2002, 106, 2642-2646.	1.6	7
41	Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. Journal of the American College of Cardiology, 2002, 40, 1140-1150.	2.8	165
42	Catheter ablation of inducible atrial flutter, in combination with atrial pacing and antiarrhythmic drugs ("hybrid therapy") improves rhythm control in patients with refractory atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 165-172.	1.3	19
43	Central Clinical Research Issues in Electrophysiology: Report of the NASPE Committee. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 526-534.	1.2	4
44	Right and left atrial activation during external direct-current cardioversion shocks delivered for termination of atrial fibrillation in humans. American Journal of Cardiology, 2001, 87, 1080-1088.	1.6	14
45	Catheter mapping of spontaneous and induced atrial fibrillation in man. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 21-28.	1.3	8
46	Benefits of new catheter mapping technology: fact or fiction?. , 2000, 4, 339-343.		2
47	New devices and hybrid therapies and new devices for treatment of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 163-169.	1.3	16
48	Don't you agree, or what part of the problem don't you understand?. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 559-560.	1.3	4
49	Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol. New England Journal of Medicine, 1999, 340, 1855-1862.	27.0	412
50	Clinical Practice Patterns in Implantable Rhythm Management Device Therapy: New Players and New Norms. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 814-815.	1.2	4
51	Evaluation of Antiarrhythmic Drug Efficacy in Patients with an ICD: Journal of Cardiovascular Electrophysiology, 1999, 10, 1534-1549.	1.7	6
52	Antiarrhythmic Device Advisories and Recalls: Managing an Increasingly Vulnerable Process. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 950-952.	1.2	7
53	Electrophysiologic study in patients with atrial fibrillation: an idea whose time has come yet again. , 1999, 3, 101-107.		1
54	Prospective clinical evaluation of a programmed atrial stimulation protocol for induction of sustained atrial fibrillation and flutter. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 19-25.	1.3	12

#	Article	IF	CITATIONS
55	Rationale and Results of Device Therapy in Atrial Fibrillation. Journal of Interventional Cardiac Electrophysiology, 1999, 3, 106-109.	1.0	O
56	Electrophysiology and endocardial mapping of induced atrial fibrillation in patients with spontaneous atrial fibrillation. American Journal of Cardiology, 1999, 83, 187-193.	1.6	54
57	Regional endocardial mapping of spontaneous and induced atrial fibrillation in patients with heart disease and refractory atrial fibrillation. American Journal of Cardiology, 1999, 84, 880-889.	1.6	54
58	Design and implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) clinical trial. DAPPAF Phase 1 Investigators. Journal of Interventional Cardiac Electrophysiology, 1998, 2, 139-144.	1.3	56
59	Regional right and left atrial activation patterns during single- and dual-site atrial pacing in patients with atrial fibrillation. American Journal of Cardiology, 1998, 82, 1197-1204.	1.6	92
60	Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention. Journal of the American College of Cardiology, 1998, 32, 1900-1908.	2.8	218
61	Acute Effects of Dual-Site Right Atrial Pacing in Patients With Spontaneous and Inducible Atrial Flutter and Fibrillation. Journal of the American College of Cardiology, 1997, 29, 1007-1014.	2.8	121
62	Interaction Between Electronic Article Surveillance Systems and Implantable Defibrillators: Insights from a Fourth Generation ICD. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2857-2859.	1.2	59
63	Internal Atrial Defibrillation: Effect on Sinus and Atrioventricular Nodal Function and Implanted Cardiac Pacemakers. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2434-2441.	1.2	22
64	Evaluation of a programming algorithm for the third tachycardia zone in a fourth-generation implantable cardioverter-defibrillator. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 49-56.	1.3	7
65	Effects of high-frequency atrial pacing in atypical atrial flutter and atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 1997, 1, 111-123.	1.3	30
66	Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. Journal of the American College of Cardiology, 1996, 28, 687-694.	2.8	267
67	Improved Survival with an Implanted Defibrillator in Patients with Coronary Disease at High Risk for Ventricular Arrhythmia. New England Journal of Medicine, 1996, 335, 1933-1940.	27.0	3,859
68	Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations. American Journal of Cardiology, 1995, 76, 913-921.	1.6	89
69	Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: An international multicenter study. Journal of the American College of Cardiology, 1994, 23, 1521-1530.	2.8	146
70	Device Use Patterns and Clinical Outcome of Implantable Cardioverter Defibrillator Patients with Moderate and Severe Impairment of Left Ventricular Function. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 179-185.	1.2	27
71	Endocardial pacing, cardioversion and defibrillation using a braided endocardial lead system. American Journal of Cardiology, 1993, 71, 834-841.	1.6	24
72	Simultaneous Biphasic Shocks Enhance Efficacy of Endocardial Cardioversion Defibrillation in Man. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1935-1942.	1.2	26

#	Article	IF	CITATIONS
73	Implantable Cardioverter Defibrillators in Cardiovascular Practice: Report of the Policy Conference of the North American Society of Pacing and Electrophysiology. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 969-979.	1.2	92
74	Initial Clinical Experience With Endocardial Defibrillation Using an Implantable Cardioverter/Defibrillator With a Triple-Electrode System. Archives of Internal Medicine, 1989, 149, 2333.	3.8	50
75	Antiarrhythmic Devices: In Search of a Common Parlance. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1579-1582.	1.2	3
76	Efficacy of Nadolol Alone or in Combination with a Type IA Antiarrhythmic Drug in Sustained Ventricular Tachycardia: A Prospective Study. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1816-1826.	1.2	5
77	Surgical Ablation of Tachyarrhythmias: Reflections for the Third Decade. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 103-108.	1.2	9